Dallas, Texas 09/16/2013 (Financialstrend) – The projection is that the global vaccine market will touch $52b by 2016. With this is view, some innovators are speeding up in innovation and trying to gain a deeper understanding with an in-depth view. Inovio Pharmaceuticals Inc (NYSEMKT:INO) is one company in this segment that has the potential to revolutionize its vaccine-technology at the base level. It specializes in DNA-based therapeutics and vaccines.
The company’s platform stimulates the immune system of the patient and helps in producing larger quantities of T-cells that fight disease and cancer. Just last week the company finalized a deal with Roche. This deal is worth approximately $50 million in equivalents and cash and the cutting-edge patented technology platform. On the whole it seems like there is a pretty bullish outlook on the future prospects of the company.
The differentiating factor
Unlike other biologic vaccines, the company’s vaccines are made up of synthetic-DNA computer generated strands that are mixed with water. This helps in giving Inovio Pharmaceuticals Inc (NYSEMKT:INO) product candidates a big lead. This is because the synthetic therapies do not run any risk of producing viruses that they are aiming to treat. Thus it is possible to manufacture them very easily and they can also be stored effectively at room temperature.
Large number of patents
These vaccines are synthetic. This has helped the company build a vast patent and IP portfolio for all its products. At the moment, Inovio’s pipeline has more than 400 patents and there are no signs that it will slow its IP expansion in any way. The one thing that the company has been patenting very aggressively so far is the coded DNA-sequences.
These are the foundational-mechanism of action for its therapies and vaccines. Via these synthesized DNA-transcription codes, the company’s vaccines operate in activating the targeted immunological responses that trigger the patient’s immune systems and help them fight disease more effectively.